MarketPulse
B

$BLCO

4 articles found
2 positive
1 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Portnoy Law Firm

Bausch + Lomb Faces Securities Fraud Investigation After 25% Stock Plunge

Portnoy Law Firm investigates Bausch + Lomb over TASS-linked intraocular lens recalls and significant stock declines following Q1 2025 guidance miss.
BLCOsecurities fraudstock decline
The Motley FoolThe Motley Fool··Jonathan Ponciano

Bausch + Lomb Posts $5.1B Revenue as Caspian Capital Doubles Down on Eye Care Bet

Bausch + Lomb posted $5.1B in annual revenue with 6% growth as Caspian Capital builds major stake, signaling institutional confidence.
BLCOrevenue growthinstitutional investment
GlobeNewswire Inc.GlobeNewswire Inc.··Visiongain

Ophthalmic Drug Market to Reach $41.88B by 2026 Amid Innovation Wave

Global ophthalmic drug market projected to reach $41.88B by 2026, growing 7.9% annually driven by biologic therapies, advanced delivery systems, and AI-enabled diagnostics.
PFEABBVNVSALCRHHBY+3AMDbiologics
GlobeNewswire Inc.GlobeNewswire Inc.··Nicox Sa

Nicox's NCX 470 Achieves Primary Efficacy Endpoints in Phase 3 Glaucoma Trial

Nicox's NCX 470 eye drop met primary efficacy endpoints in Phase 3 glaucoma trials, showing superior IOP reduction versus standard treatment with favorable safety profile.
BLCOPhase 3 clinical trialFDA approval